Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).
J Allergy Clin Immunol Pract
; 11(7): 2248-2250.e3, 2023 07.
Article
in En
| MEDLINE
| ID: mdl-37088371
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Mastocytosis
/
Anti-Allergic Agents
/
Mastocytosis, Cutaneous
/
Mastocytosis, Systemic
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
J Allergy Clin Immunol Pract
Year:
2023
Document type:
Article
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA